Core Insights - BlackLine, Inc. actively engages with its stockholders, having met with Engaged Capital seven times in the past 12 months, demonstrating a commitment to constructive dialogue with all shareholders [1] Company Overview - BlackLine (Nasdaq: BL) is a platform designed for the Office of the CFO, focusing on digital finance transformation by providing accurate, efficient, and intelligent financial operations [2] - The company utilizes the Studio360 platform to unify data, streamline processes, and deliver real-time insights through automation and AI capabilities powered by Verity [2] Customer Base and Innovation - BlackLine has over 4,400 customers across various industries, indicating a broad market presence and a collaborative approach to innovation [3]

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Biotech Valuations Rise as New Clinical Platforms Show Progress ...

Core Insights - Fairchild Gold Corp. has joined the Critical Minerals Forum (CMF), enhancing its position in the critical minerals supply chain and reaffirming its commitment to domestic production of copper, gold, platinum-group metals, antimony, and cobalt in the U.S. [1][3] Company Overview - Fairchild Gold Corp. is focused on mineral exploration and development, particularly in copper and gold assets in Nevada, aiming to create long-term shareholder value through disciplined exploration and strategic partnerships [8]. Strategic Benefits of CMF Membership - Membership provides direct access to U.S. federal agencies and policymakers, facilitating engagement in critical minerals strategy [7] - Access to advanced data analytics and forecasting models developed through DARPA's OPEN initiative, offering market intelligence across various policy scenarios [7] - Opportunities for capital market participation through a project clearinghouse that connects member companies with investors focused on critical minerals supply chain development [7] - Collaboration with over 55 companies across the critical minerals value chain, including major players in the electric vehicle, battery, semiconductor, defense, and aerospace industries [2][3] Industry Context - The CMF aims to strengthen secure, resilient, and transparent supply chains for critical minerals, reflecting the growing momentum behind U.S. efforts to expand domestic production capacity [3][5].

LOWELL, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced the promotion of Robert Dennehy to Chief Operating Officer (“COO”). In this role, Mr. Dennehy will continue to oversee MACOM's global operations, manufacturing, supply chain and operational strategies as the company continues to grow and serve its diverse customer base. Mr. Dennehy’s comprehensive knowledge of the company's operati ...

Core Viewpoint - Houston American Energy Corp. plans to change its name to Abundia Global Impact Group Inc. and its ticker symbol from HUSA to AGIG on NYSE American, reflecting its focus on sustainable fuels and energy transition technologies following the acquisition of Abundia Global Impact Group LLC [1][2]. Group 1: Company Strategy and Vision - The name change signifies the Company's long-term vision to build a scalable platform in circular fuels, sustainable feedstocks, and next-generation low-carbon energy solutions [2]. - The Company aims to advance technologies that convert waste plastics and renewable feedstocks into low-carbon fuels, chemical intermediates, and clean energy products, positioning itself in a rapidly growing segment of the global energy economy [2]. - The Abundia platform is expected to provide a strong foundation for long-term value creation, supported by the development of the Cedar Port Renewable Energy Complex and the integration of circular-fuels technologies [2]. Group 2: Recent Developments - In July 2025, Houston American Energy Corp. acquired Abundia Global Impact Group LLC, which specializes in converting waste plastics into low-carbon fuels and chemical feedstocks, reflecting a commitment to meeting global energy demands through a mix of traditional and alternative energy solutions [3]. - The strategic acquisition positions the Company to capitalize on emerging opportunities in sustainable fuels and energy transition technologies [3].

Core Insights - VCI Global Limited has announced a strategic partnership with Oobit to enhance access to the global payment market through a new crypto-to-fiat settlement infrastructure [1][2] - The collaboration aims to enable instant fiat conversion for merchants in ASEAN and other emerging markets, addressing gaps in financial infrastructure and payment accessibility [3][9] Group 1: Partnership and Infrastructure - Oobit's platform allows consumers to pay using major digital assets while merchants receive real-time fiat settlement in local currencies [2][4] - The partnership will focus on accelerating merchant onboarding and enterprise integrations, particularly targeting the underserved SME sector in ASEAN [3][5] - Voobit, a next-generation settlement rail, will be developed to operate independently of traditional card networks, providing a scalable alternative for small businesses [5][10] Group 2: Market Opportunity and Growth - The global payments market is projected to reach approximately US$3.12 trillion by 2025, with significant growth expected towards 2030 [8] - SMEs in ASEAN represent a large portion of the private sector but often face financing and structural gaps that limit access to modern payment systems [8][9] - Voobit aims to provide instant, compliant, and cost-efficient crypto-to-fiat settlement, helping SMEs overcome fragmented payment infrastructure and unlock new revenue streams [9][10]

Core Insights - Biomerica, Inc. has announced the publication of a large multicenter clinical trial demonstrating the effectiveness of its inFoods® IBS diagnostic-guided therapy in managing Irritable Bowel Syndrome (IBS) symptoms [1][3][10] Study Overview - The clinical trial was randomized, multicenter, double-blind, and placebo-controlled, evaluating the inFoods® IBS test's ability to identify patient-specific dietary triggers and guide targeted food elimination [2][4] - The study involved 223 IBS patients across eight major U.S. academic medical centers, including renowned institutions like Mayo Clinic and Harvard Beth Israel Deaconess Medical Center [4] Key Findings - Patients following the inFoods® IBS-guided elimination diet experienced significantly greater symptom relief, with 59.6% achieving the FDA-defined target for abdominal pain reduction compared to 42.1% in the control group [9] - Particularly strong results were noted in difficult-to-treat IBS subtypes, with 67.1% of IBS-C patients and 66.0% of IBS-M patients responding positively to the treatment [9] Methodology and Innovation - The inFoods® IBS assay utilizes a proprietary discriminatory p-value method to identify foods causing abnormal IgG responses unique to IBS patients, allowing for a more focused dietary approach [7][10] - The study design addressed limitations of previous research by employing an IBS-specific food panel and robust statistical methodology, enhancing the reliability of the findings [6][10] Clinical Implications - The results support a shift towards precision medicine in gastrointestinal care, where individualized biological markers guide tailored treatment decisions rather than generalized approaches [12][11] - The inFoods® IBS protocol typically results in the elimination of only 2 to 4 foods per patient, making it a more practical and sustainable option compared to broader dietary strategies like the low-FODMAP diet [8][10] Recognition and Future Outlook - The inclusion of inFoods® IBS in Biotherapeutics Quarterly highlights the growing recognition of Biomerica's innovation among healthcare professionals [13] - The study's outcomes underscore the potential of diagnostic-guided dietary strategies to address unmet clinical needs, particularly for IBS-M patients, for whom no FDA-approved medications currently exist [11][12]

Core Insights - Teva Pharmaceuticals has received marketing authorizations from the European Commission for two denosumab biosimilar candidates, PONLIMSI and DEGEVMA, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) earlier this year [1][9]. Group 1: Product Approvals - The approvals of PONLIMSI and DEGEVMA represent a significant milestone in Teva's biosimilars portfolio, enhancing patient access to essential biologic therapies across Europe [2][9]. - Teva plans to launch both products in key European markets in the coming months, aligning with its Pivot to Growth strategy [2][9]. Group 2: Product Details - PONLIMSI is indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, as well as for bone loss associated with hormone ablation in men with prostate cancer [4][6]. - DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer involving bone and for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone [7][10]. Group 3: Mechanism of Action - Both PONLIMSI and DEGEVMA contain denosumab, a human monoclonal IgG2 antibody that targets the protein RANKL, crucial for the formation and survival of osteoclasts, thereby reducing bone resorption [5][8]. - PONLIMSI will be available as a 60mg/1mL solution for injection in a pre-filled syringe, while DEGEVMA will be available as a 120mg/1.7mL solution for injection in a vial [5][8]. Group 4: Company Commitment - Teva's leadership emphasizes the importance of these approvals in increasing patient access to biosimilar therapies for serious bone conditions, reflecting the company's commitment to improving healthcare options in Europe [3][9]. - The company aims to provide additional treatment options for healthcare systems, particularly in regions where access to biosimilars is limited [3].

Core Insights - Nanox Imaging Ltd has entered into a distribution agreement with Althea France to introduce its CE-marked Nanox.ARC system in the French healthcare sector, marking its fourth distribution agreement in Europe [1][2][3] Company Overview - Nanox is focused on advancing medical imaging technology, aiming to drive the transition to preventive healthcare through affordable solutions that leverage AI and proprietary digital X-ray sources [4][5] Partnership Details - Althea France will manage the market introduction, sales, and service of the Nanox.ARC, which is a multi-source digital tomosynthesis system designed to enhance diagnostic capabilities at a lower cost compared to traditional systems [2][3] - The partnership is expected to leverage Althea's established relationships with hospitals and clinics across France, facilitating the introduction of Nanox's imaging platform [3] Market Strategy - France is identified as a strategic market for Nanox, with the partnership expected to expand access to high-quality, affordable imaging services for patients [3] - The collaboration follows previous agreements in Greece, Romania, and the Czech Republic, indicating a growing presence in the European market [1][2]

Core Points - Golar LNG Limited has successfully closed a new $1.2 billion asset-backed debt facility agreement for refinancing FLNG Gimi, replacing an existing facility with an outstanding amount of $627 million as of Q3 2025 [1][2] - The new debt facility has a 7-year tenor, a 16-year amortization profile, and incurs interest at SOFR plus a margin of 2.50% per annum [2] - Golar's 70% share of the net liquidity released from the refinancing amounts to approximately $400 million after repaying the existing Gimi debt facility and unwinding the existing interest-rate swap [2] - The CEO of Golar, Karl Fredrik Staubo, expressed satisfaction with the strong interest from leading international banks, indicating improved terms compared to the initial financing facility [3] - The new facility demonstrates the bankability of Golar's FLNG assets once operational, with a projected debt to EBITDA ratio of approximately 5.5x [3]